Data on pregnancies with and without Down's syndrome between 10 and 14 weeks of pregnancy were used to determine the performance of combined ultrasound and biochemical markers in prenatal screening for Down's syndrome. We used three datasets: one published by on nuchal translucency measurement in 8
Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland
✍ Scribed by Niemimaa, Marko; Suonpää, Mikko; Perheentupa, Antti; Seppälä, Maija; Heinonen, Seppo; Laitinen, Päivi; Ruokonen, Aimo; Ryynänen, Markku
- Book ID
- 110025139
- Publisher
- Nature Publishing Group
- Year
- 2001
- Tongue
- English
- Weight
- 98 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1018-4813
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
To assess the value of inhibin A as an additional second-trimester maternal serum marker of Down's syndrome we studied 56 affected and 280 unaffected pregnancies matched for gestational age. The median level in the cases was 1.62 multiples of the gestation-specific median (MOM) in the controls, with
We have carried out a large retrospective study of -fetoprotein (AFP), free-human chorionic gonadotrophin (hCG) and pregnancy-associated plasma protein (PAPP-A) in the first trimester of pregnancy. Unlike other studies all women had routine ultrasound dating, carried out during a nuchal translucency
Second-trimester maternal serum screening for fetal Down's syndrome is well established in many Western countries. Its usefulness and acceptability is unknown in the Asian countries. Between June 1994 and December 1996, we offered second-trimester serum AFP and hCG screening to pregnant women in Hon